San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) will present 24-month skeletal muscle and cardiac data from its Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) at the World Muscle Society Congress, weeks ahead of an FDA PDUFA target action date of November 22, 2026.

The 31st Annual Congress (WMS 2026) runs September 29 to October 3, 2026, in Hiroshima, Japan. Capricor will deliver one late-breaking poster and one oral presentation on Deramiocel, plus two preclinical posters from its StealthX exosome platform.

Stockholm – October 19, 2026 -- Sobi will present seven accepted abstracts on Aspaveli/Empaveli (pegcetacoplan) at the American Society of Nephrology (ASN) Kidney Week 2026, running 21–25 October in Denver, Colorado, including two oral and five poster presentations.

Indianapolis – October 18, 2026 -- Eli Lilly and Company (NYSE: LLY) will present first Phase 1 data for its investigational FRα-targeting antibody-drug conjugate sofetabart mipitecan (Sofe-M) in platinum-sensitive ovarian cancer (PSOC) at the European Society for Medical Oncology (ESMO) Congress, October 23–27 in Madrid, alongside updated data across lung, thyroid and breast cancer programs.

North Chicago – October 18, 2026 -- AbbVie will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology (ESMO) Congress, October 23-27 in Madrid, the company's most expansive ESMO program to date. The data span lung, colorectal, ovarian, prostate and gastric cancers, across antibody-drug conjugates (ADCs), bispecific antibodies and combination regimens.

North Chicago – October 17, 2026 -- AbbVie (NYSE: ABBV) is presenting 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17-20 in Barcelona, Spain. The data cover long-term and real-world outcomes for Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn's disease (CD) and ulcerative colitis (UC).

TORONTO – October 14, 2026 -- Patients treated with whole-gland TULSA were more than twice as likely to preserve both erectile function and pad-free continence at six months as those who had robotic radical prostatectomy (risk ratio 2.1; p=0.004), according to CAPTAIN trial data. Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) presented the results among five abstracts at the 15th Interventional MRI Symposium in Boston.

Geneva – October 14, 2026 -- MindMaze Therapeutics (SIX: MMTX) reported that home-based rehabilitation with its MindMotion platform raised total motor-training dose by a median factor of 3.0 versus usual outpatient therapy alone, with 84% of active training completed without direct therapist supervision.

The multi-site program, run with Vibra Healthcare, was presented at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The data arrive ahead of the company's MindMotion Lite launch, expected by year-end 2026.

Caesarea, Israel – October 13, 2026 -- IceCure Medical (Nasdaq: ICCM) reported 12-month objective response rates of 97.5% among 40 breast cancer patients treated with ProSense® cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands.

Friendswood – October 12, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.

The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.

Dublin – October 12, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.